Abaloparatide ƒe atike 3mg

▎ Abaloparatide ƒe Dɔwɔɖoɖo

▎ Abaloparatide Ŋuti Numekuku

Nukae nye numekuku si wowɔ tso abaloparatide ŋu?

Ƒumeŋuɖui nye ƒumeŋuɖui ƒe dɔléle si bɔ si tsoa nu geɖe gbɔ si ƒe dzesi enye ƒu ƒe lolome sue kple ƒu ƒe lãkusi ƒe gbegblẽ le xɔtuɖaŋu suewo me. Esia nana ƒu ƒe gbagbã dzina ɖe edzi eye wòte ŋu gbãna bɔbɔe, eye akɔta kple aklã ƒe gbagbã nyea emetsonu siwo bɔ. Ekpɔa ŋusẽ ɖe dɔnɔwo ƒe agbenɔnɔ ƒe nyonyome dzi vevie eye wòdzia ​​nuwɔametɔnyenye kple ku ƒe agbɔsɔsɔ ɖe edzi. Esi xexeame katã ƒe amewo le tsitsim kabakaba ta la, ƒumeŋuɖui ƒe dzɔdzɔ yi edzi le dzidzim ɖe edzi. Wobu akɔnta be nyɔnu 42%-56% kple ŋutsu siwo xɔ wu ƒe 50 ƒe 27%-29% akpɔ ƒu ƒe gbagbã, si wɔe be wòanye dukɔa ƒe lãmesẽnya kpata. Ƒumeŋuɖui ƒe dɔdamɔnu siwo wozãna tsã, abe bisphosphonates kple selective estrogen receptor modulators (SERMs) ene, koŋue léa ƒu ƒe kpekpeme ɖe te to mɔxexe ɖe ƒu ƒe ʋuʋu si ƒumeŋuɖuiwo tona nu. Gake woƒe dɔwɔwɔ mesɔ gbɔ na dɔnɔ siwo ƒe ƒu ƒe lolome dzi ɖe kpɔtɔ ŋutɔ eye woƒe ƒu gbagbã ƒe afɔku gã aɖe le wo ŋu o. Togbɔ be parathyroid hormone (PTH) 1-34 fragment (teriparatide) ye nye anabolic agent gbãtɔ si dzi United States Nuɖuɖu Kple Atike Ŋuti Dɔwɔƒe (FDA) da asi ɖo, si dzia ƒu ƒe kpekpeme ɖe edzi nyuie eye wòɖea ƒu ƒe gbagbã ƒe afɔku dzi kpɔtɔna hã la, ezazã ɣeyiɣi didi hea seɖoƒe siwo dometɔ aɖewoe nye ƒu ƒe gbugbɔgaxɔ ƒe dzidziɖedzi, hypercalcemia, kple osteosarcoma ƒe afɔku si ate ŋu adzi ɖe edzi.

Le nɔnɔme sia ta la, atike yeye siwo ƒoa atike sesẽ siwo naa ʋumenugbagbeviɣidɔ nu ƒu esime wole asa ƒom na kuxi siawo toto vɛ le vevie ŋutɔ. Abe parathyroid hormone-related peptide (PTHrP) analog ene la, abaloparatide léa anabolic dɔwɔwɔ sesẽ me ɖe asi esime wòɖea ŋusẽ si wòkpɔna ɖe ƒu ƒe gbugbɔgaxɔ dzi dzi kpɔtɔna eye wòɖea serum calcium ƒe tɔtrɔ dzi kpɔtɔna, si wɔnɛ be wòɖea vi na ƒumeŋuɖui.

Nukawoe nye mɔnu siwo dzi abaloparatide wɔa dɔ le?

Nuwɔwɔ Kple Parathyroid Lãmetsiŋusẽ Xɔla 1 (PTH1R) .

Receptor Selective Activation: Abaloparatide nye atike si tiaa parathyroid hormone receptor 1 (PTH1R) ƒe dɔlékuiwutike. PTH1R dzena le lãmenugbagbeviwo ƒe gowo dzi le lãkusiwo abe ƒu kple ayiku ene me, eye wòwɔa akpa vevi aɖe le ƒu ƒe lãmenugbagbeviwo ƒe dɔwɔwɔ dzi kpɔkpɔ me. Abaloparatide blana ɖe PTH1R ŋu koŋ, si dzea lãmenugbagbeviwo me dzesimɔ vovovowo gɔme be woatsɔ aɖɔ ƒu ƒe lãmenugbagbeviwo ƒe dɔwɔwɔ ɖo. Ne ebla ɖe eŋu la, enaa adenylate cyclase wɔa dɔ, si wɔnɛ be lãmenugbagbeviwo me cyclic AMP (cAMP) wɔwɔ dzina ɖe edzi be wòatrɔ asi le lãmenugbagbeviwo ƒe dɔwɔwɔ kple woƒe lãmenugbagbeviwo ƒe dɔwɔwɔ ŋu ^[1,2]..

Vovototo siwo le ligand bubuwo dome: Parathyroid hormone (PTH) kple parathyroid hormone-related protein (PTHrP) hã blana ɖe PTH1R ŋu. Togbɔ be PTH, PTHrP, kple Abaloparatide katã na dzesi to PTH1R dzi hã la, woƒe dzesimɔ siwo le anyime la to vovo. PTH kple PTHrP ɖea ƒomedodo ɖeka tɔgbe fiana na PTH1R ƒe R ^ G (GTPγS-sensitive) nɔnɔme. Teriparatid (TPTD, i.e., 1–34 PTH) ƒe lɔlɔ̃ na R ^ 0 (GTPγS-insensitive) nɔnɔmea sɔ gbɔ wu PTHrP zi gbɔ zi ene, si wɔnɛ be cAMP ƒe dzesi didi si TPTD hena vɛ. To vovo na ema la, wotrɔ asi le abaloparatide, si woɖe tso PTHrP(1–34) me ŋu be wòana wòali ke nyuie wu eye wòɖua nyawo abe anabolic fesre ƒe bu kple hypercalcemia si do ƒome kple TPTD zazã dzi. Esi wònye be PTHrP-PTH1R ƒe ƒuƒoƒoa ƒe mama kabakaba wu PTH-PTH1R ƒe ƒuƒoƒoa tɔ ta la, PTHrP ƒe ƒumeŋuɖui ƒe ŋusẽkpɔɖeamedziwo kpena ɖe PTHrP ƒe ƒumeŋuɖui ƒe ŋusẽkpɔɖeamedzi si mebɔ o kple calcemia si sɔ gbɔ wu TPTD ŋu. Abaloparatide nyi viɖe sia si sɔ gbɔ la ƒe dome ^[1,2,3]..

Ƒuwo ƒe Dɔwɔnawo ƒe Dɔwɔnawo Dzikpɔkpɔ

Ƒumeŋuɖui dodo ɖe ŋgɔ: Abaloparatide doa ŋusẽ ƒumeŋuɖui ƒe dɔwɔwɔ, si naa ƒu ƒe wɔwɔme kple ƒu ƒe ƒuƒu dzina ɖe edzi be wòado ƒu ƒe wɔwɔme ɖe ŋgɔ. Ƒumeŋuɖuiwo wɔa ƒu ƒe akpa siwo le abe collagen kple osteocalcin ene eye woɖea wo ɖe go, eye vivivi la, wozua mineral va wɔa ƒu ƒe lãkusi yeyewo. Numekukuwo ɖee fia be le ƒumeŋuɖui le dzinukpɔkpɔ megbe dada me la, abaloparatide dzia ƒu ƒe mineral density (BMD) ɖe edzi ŋutɔ le teƒe siwo dometɔ aɖewoe nye akɔta bliboa, akɔta ƒe kɔ, kple akɔta ƒe akɔta. To domenyiŋusẽfianu siwo do ƒome kple ƒumeŋuɖui ƒe ɖeɖefia me la, edoa protein veviwo abe osteocalcin kple collagen ƒomevi I ƒe wɔwɔ ɖe dzi. Esia doa trabecular thickening kple cortical ŋusẽdodo ɖe ŋgɔ, si doa ŋusẽ ƒuwo ƒe ŋusẽ kple nyonyome esime wòɖea ƒu ƒe gbagbã ƒe afɔku dzi kpɔtɔna ^[1,2,3]..

Ƒu ƒe Ʋuʋu ƒe Mɔxexe Nu: Togbɔ be Abaloparatide wɔa dɔ koŋ abe ƒu ƒe ʋuʋu ene hã la, eɖea mɔxexe ɖe ƒu ƒe ʋuʋu nu ƒe ŋusẽkpɔɖeamedzi aɖewo hã fiana. Etrɔa asi le ƒumeŋuɖuiwo ƒe vovototodedeameme kple dɔwɔwɔ ŋu—lãmenugbagbevi siwo ƒe dɔe nye be ƒu ƒe gbugbɔgaxɔ si ƒoa ƒu ƒe mineral kple organic matrix to asidinuwo kple proteolytic enzymes ƒe dodo me. Abaloparatide ate ŋu aɖe ƒu ƒe gbugbɔgaxɔ ƒe agbɔsɔsɔ dzi akpɔtɔ to ƒumeŋuɖui ƒe lãmenugbagbevi siwo do ŋgɔ na ƒumeŋuɖui ƒe vovototodedeameme dzi ɖeɖe kpɔtɔ va zu ƒumeŋuɖui tsitsiwo alo ƒumeŋuɖui tsitsiwo ƒe agbenɔƒe dzi ɖeɖe kpɔtɔ me. Le ɣeyiɣi ma ke me la, etrɔa asi le dzesi siwo le ƒumeŋuɖuiwo kple ƒumeŋuɖuiwo dome ŋu, si wɔnɛ be ƒu ƒe wɔwɔme kple ƒumeŋuɖui ƒe dadasɔ si me ŋusẽ le la nɔa anyi. Le kpɔɖeŋu me, eɖea ƒumeŋuɖui ƒe dɔwɔwɔ kple ƒumeŋuɖui ƒe dɔwɔwɔ dzi kpɔtɔna to ƒumeŋuɖui-secreted receptor activator of nuclear factor κB ligand (RANKL) dzi ɖeɖe kpɔtɔ me. To vovo na teriparatide la, abaloparatide medzia RANKL ƒe wɔwɔ ɖe edzi fũ o, si wɔnɛ be anabolic fesre si dzɔna ne resorption xɔ ŋgɔ le wɔwɔme le afɔɖeɖe siwo va yi me la ƒe bu ^[1,2,3]..

Nɔnɔmetata 1 Parathyroid lãmetsiŋusẽ (PTH)/teriparatide kple peptide si do ƒome kple PTH (PTHrP/abaloparatide ƒe dɔwɔwɔ le parathyroid lãmetsi ƒomevi 1 xɔla (PTH1R)) ƒe kpɔɖeŋu ^[4]..

Ŋusẽkpɔɖeamedzi ɖe ƒunukpeƒetetedɔ Ŋu (le Numekuku Siwo Ku Ðe Ƒumeŋuɖui Ŋu me)

Doa Ƒumeŋuɖui ƒe Matrix ƒe Dɔwɔwɔ Ðe ŋgɔ: Numekuku siwo wowɔ le ƒunukpeƒetetedɔ (OA) ŋu ɖee fia be abaloparatide kpɔa ŋusẽ ɖe ƒunukpeƒewo ta. Articular chondrocytes ɖea PTH1R fiana, eye Abaloparatide naa receptor sia wɔa dɔ, si ʋãa chondrocytes be woawɔ cartilage matrix ƒe akpa aɖewo. Le kpɔɖeŋu me. Edoa kolagen ƒomevi II, si nye ƒunukpeƒeŋusẽ ƒe akpa vevitɔ hã ƒe wɔwɔ ɖe ŋgɔ, si kpena ɖe ƒunukpeƒea ƒe wɔwɔme kple dɔwɔwɔ ƒe blibonyenye ŋu. To ƒunukpeƒetetedɔ ƒe akpa siawo ƒe wɔwɔme dzi ɖeɖe kpɔtɔ me la, Abaloparatide kpena ɖe ƒunukpeƒeŋusẽ ƒe lãkusi siwo gblẽ la dzadzraɖo kple wo takpɔkpɔ ŋu, si wɔnɛ be ƒunukpeƒetetedɔ ƒe ŋgɔyiyi dzi ɖena kpɔtɔna ^[5]..

Mɔxexe ɖe chondrocyte ƒe dzidziɖedzi kple woƒe gbegblẽ nu: Abaloparatide ate ŋu atɔ te chondrocytes ƒe vovototodedeameme si lolo akpa. Le ƒunukpeƒetetedɔ ƒe ŋgɔyiyi me la, ƒunukpeƒetetedɔ toa vovototodedeameme si lolo akpa me, si ƒe dzesi enye lãmenugbagbeviwo ƒe lolome dzina ɖe edzi kple dzidziɖedzi ƒe dzesi tɔxɛwo abe ƒomevi X collagen (Col10) ene ƒe ɖeɖefia dzina ɖe edzi. Nuwɔna sia hea ƒunukpeƒe ƒe lãkusi ƒe gbegblẽ kple ƒunukpeƒe ƒe gbegblẽ vɛ. Numekukuwo ɖee fia be Abaloparatide zazã ɖea Col10 ƒe ɖeɖefia ƒe dziyiyi dzi kpɔtɔna le ƒunukpeƒeŋusẽ me esime wòɖea lãmenugbagbevi gã siwo le abe hypertrophic ene ƒe xexlẽme dzi kpɔtɔna. Esia fia be ate ŋu ana ƒunukpeƒeŋusẽ ƒe vovototodedeameme si lolo akpa nagbɔdzɔ, alé ƒunukpeƒeŋusẽ ƒe nɔnɔme si sɔ la me ɖe asi, si ana wòakpɔ ƒunukpeƒeŋusẽ ta eye wòahe ƒunukpeƒetetedɔ ƒe ŋgɔyiyi ɖe megbe ^[5]..

Nukae nye Abaloparatide zazã?

Ƒumeŋuɖui ƒe Atikewɔwɔ

Ƒumeŋuɖui le dzinukpɔkpɔ megbe: Wofia abaloparatide, si nye parathyroid hormone receptor 1 (PTHR1) ƒe atike tiatia aɖe be woatsɔ ada ƒumeŋuɖui, vevietɔ le nyɔnu siwo ƒe dzinukpɔkpɔ megbe siwo ƒe afɔku le be woagbã alo womewɔa nu ɖe ​​atike bubuwo ŋu o gome. Edzia ƒumeŋuɖui ƒe agbɔsɔsɔ ɖe edzi ŋutɔ eye wòɖea akɔta kple akɔta ƒe gbagbã yeyewo ƒe dzɔdzɔ kple afɔku dzi kpɔtɔna le nyɔnu siwo tsi dzinu megbe.

Ŋutsu ƒe Ƒumeŋuɖui: Le Chandler H ƒe numekuku si wòwɔ le ŋutsu ƒe ƒumeŋuɖui ŋu to sisiblisi siwo woɖe orchidectomized (ORX rats, ŋutsu ƒe ƒumeŋuɖui ƒe kpɔɖeŋu) zazã me la, Abaloparatide zazã na BMD dzi ɖe edzi geɖe wu si wodzidze to dual-energy X-ray absorptiometry (DXA) kple peripheral quantitative computed tomography (pQCT) me le teƒe siwo ŋutilã bliboa hã le, akɔta ƒe akɔta, afɔkpodzi, kple afɔkpodzi. Ena trabecular ƒe wɔwɔme, ƒu ƒe lolome, kple microarchitecture nyo ɖe edzi ŋutɔ evɔ medzi osteoclast ƒe xexlẽme ɖe edzi o. Esia fia be Abaloparatide lé viɖe siwo ate ŋu anɔ ŋutsuwo ƒe ƒumeŋuɖui ƒe atikewɔwɔ me ^{[6] .}.

Ƒunukpeƒetetedɔ (PTOA) ƒe Atikewɔwɔ: Le klo ƒe PTOA dodo ɖe ŋgɔ to medial meniscus destabilization (DMM) dɔwɔwɔ me le C57BL/6 mice ŋutsu siwo xɔ kwasiɖa 16 megbe la, wodo Abaloparatide 40 μg/kg (alo saline abe alesi woakpɔ edzi ene) gbesiagbe le ŋutigbalẽ te tso kwasiɖa 2 le amekokoa megbe hena Kwasiɖa 6 sɔŋ. Wowɔ lãmenugbagbeviwo me dzodzro le kwasiɖa 8 megbe. Emetsonuwo ɖee fia be ne wotsɔe sɔ kple ƒuƒoƒo si wotsɔ saline da dɔe la, ƒuƒoƒo si wotsɔ Abaloparatide da dɔe la ɖe DMM-si na ƒunukpeƒetetedɔ ƒe bu dzi ɖe kpɔtɔ eye wòkpɔ tibial surface cartilage tissue ta. Dɔlélenutsiŋutete ƒe lãmenugbagbeviwo me dzodzro ɖee fia be Abaloparatide zazã ɖe ƒomevi X ƒe collagen (Col10) ƒe dziyiyi dzi kpɔtɔ le ƒunukpeƒewo, ena lubricin (Prg4) ƒe ɖeɖefia dzi ɖe edzi le ƒunukpeƒe siwo me calcified mele o me, eye wòɖe lãmenugbagbevi gã siwo tsina fũu akpa ƒe xexlẽme dzi kpɔtɔ. si fia be Abaloparatide naa vovototodedeameme si gbɔ eme ƒe vovototodedeameme nɔa blewu eye wòwɔa dɔ ɖe ame ƒe lãkusi ta le sisiblisi ƒe PTOA me, si naa atikewɔwɔmɔnu yeye aɖe na PTOA ^[5]..

Alveolar Bone Regeneration: Alveolar bone resorption le eɖeɖe vɔ megbe xea mɔ na aɖuɖɔɖɔɖɔ ƒe ʋuʋu (OTM) alo aɖuɖɔɖɔɖɔ si kplɔe ɖo la vevie. Tan B wɔ calcium phosphate nanoblossoms (NFs) siwo te ŋu gblẽna, siwo wɔa dɔ eve siwo me Abaloparatide (ABL) le, siwo woyɔna be ABL@NFs. Nu sia ɖea porous layered structure, atike encapsulation ƒe dɔwɔwɔ nyuie, kple biocompatibility nyuitɔ kekeake fiana. Woɖe asi le ABL ŋu gbã be woaxɔ lãmenugbagbeviwo, eye emegbe woɖe Ca⊃2;+ kple PO4⊃3;− ɖe go atraɖii hena in situ interfacial mineralization. Esia na ƒu si le dɔ wɔm le nɔnɔme kple dɔwɔwɔ me la gaɖo anyi dzidzedzetɔe evɔ megblẽ OTM me o ^[7]..

Refractory Hypoparathyroidism (HPT): Chamseddin R ka nya ta be nyɔnu aɖe si xɔ ƒe 39 si ŋu iatrogenic HPT le si mete ŋu ɖo serum calcium ƒe agbɔsɔsɔ si sɔ gbɔ o togbɔ be wodo vitamin D geɖe, calcium kpeɖeŋutɔ, kple PTH (rPTH) si wogbugbɔ ƒo ƒu do nɛ hã. Le abaloparatide dodo ɖe ŋutigbalẽ te to Simplicity patch dzi kple ŋkuléle ɖe eŋu nyuie kple agbɔsɔsɔme si wòzãna na ame ŋutɔ megbe la, eƒe serum calcium gakpɔtɔ li ke le 9 mg/dL le ɣleti 2 megbe. Kaka wòaxɔ ɣleti 4 la, elé serum calcium si sɔ me ɖe asi evɔ hypocalcemia ƒe ɣeyiɣi aɖeke menɔ eŋu o esime wònɔ calcium kple vitamin D si woano dzi ɖem kpɔtɔ vivivi ^[3]..

Akɔta ƒe Fuɖename Dodo Ðe Ŋgɔ: Le vidzidɔ kple akɔta ƒe gbugbɔgaɖɔɖo ƒe amekoko me la, wozã abaloparatide tsɔ do aklã ƒe ƒoƒo ɖe ŋgɔ le dɔnɔ siwo ƒe ŋutinya me vidzidɔ meli ke o eye wowɔ dɔ na wo zi geɖe do kpo nu. Parikh S kple ame bubuwo. ka nya ta be nyɔnu dɔnɔ aɖe si xɔ ƒe 66 si dze Abaloparatide mcg 80 zazã gɔme gbesiagbe le kwasiɖa eve megbe le dɔwɔwɔ nɛ vɔ megbe hena kwasiɖa 12 ƒe atikewɔwɔ si ŋu wowɔ ɖoɖo ɖo. Vidzidɔ ƒe CT-dɔdamɔnu siwo wowɔ le ɣleti 3 kple 6 me ɖee fia be vidzidɔ kple akɔta ƒe ƒoƒo ɖekae haya nyuie eye dzesi aɖeke menɔ eŋu be womewɔ ɖeka o ^[8]..

Nyanuwuwuw

Abaloparatide ƒe dɔdamɔnu zazã ku ɖe ƒumeŋuɖui dada ŋu. Wofiae na nyɔnu siwo ƒe dzinukpɔkpɔ wu enu siwo ŋu ƒumeŋuɖui le siwo ƒe ƒuwo ƒe gbagbã ƒe afɔku gã aɖe le alo womewɔa nu ɖe ​​atike bubuwo ŋu o, si dzia ƒu ƒe mineral density (BMD) ɖe edzi ŋutɔ eye wòɖea akɔta kple esiwo menye akɔta ƒe gbagbã ƒe afɔkua dzi kpɔtɔna. Le ŋutsuwo ƒe ƒumeŋuɖui gome la, numekuku siwo wowɔ le lãwo ŋu ɖee fia be BMD dzi ɖe edzi le teƒe geɖe eye ƒu ƒe wɔwɔme suesuesuewo nyo ɖe edzi, si ɖee fia be viɖe ate ŋu anɔ atikewɔwɔ me. Le ƒunukpeƒetetedɔ si dzɔna le afɔku megbe me la, eɖea ƒunukpeƒetetedɔ ƒe bu dzi kpɔtɔna eye wòxea mɔ na ƒunukpeƒetetedɔ ƒe dzidziɖedzi be wòakpɔ ƒunukpeƒewo ta. Le ƒu ƒe gbugbɔgadzɔ me la, ABL@NFs nusiwo me atike sia le doa ƒu ƒe gbugbɔgadzɔ ɖe ŋgɔ, si naa egbɔkpɔnu na ƒu ɖɔɖɔɖo le aɖuɖɔɖɔɖɔ megbe. Numekukuwo hã ɖo kpe edzi be wozãnɛ le refractory hypoparathyroidism kple spinal fusion dodo ɖe ŋgɔ me.

Le Agbalẽŋlɔla La Ŋu

Nusiwo míeyɔ ɖe etame la katã nye esiwo ŋu Cocer Peptides wɔ numekuku le, trɔ asi le wo ŋu eye woƒo wo nu ƒu.

Dzɔdzɔmeŋutinunya ƒe Agbalẽŋlɔla

Bin T nye numekula le Dzɔdzɔmeŋusẽŋununya ƒe Dɔwɔƒe, Peking Yunivɛsiti, si bi ɖe nanomaterials kple wo zazã le nugbagbeŋutinunya me. Eƒe dɔa ku ɖe nanostructures siwo wɔa dɔ ƒe ɖoɖowɔwɔ kple wo wɔwɔ ŋu hena atikewo ɖoɖo ɖe taɖodzinu si woɖo taɖodzinu na kple lãmenugbagbeviwo ƒe gbugbɔgawɔ. Tan kpe asi ɖe agbalẽ gbogbo aɖewo siwo wota le dzɔdzɔmeŋutinunya ƒe magazine xɔŋkɔwo me ŋu, eye wòkpe asi ɖe ŋgɔyiyi siwo wowɔ le nanomedicine kple gbugbɔgawɔ ƒe atikewɔwɔwo me. Woŋlɔ Bin T ɖe nyayɔyɔ ƒe numekugbalẽ me [7].

▎ Nyayɔyɔ Siwo Sɔ

[1] Shirley M. Abaloparatide: Xexeame Katã ƒe Mɔɖeɖe Gbãtɔ. Atike vɔ̃ɖiwo ƒe 2017; 77 (12): 1363-1368.DOI: 10.1007/s40265-017-0780-7.

[2] Sleeman A, Clements J. N., kple ame bubuwo. Abaloparatide: Atike yeye aɖe si wozãna na ƒumeŋuɖui. Amerikatɔwo ƒe Lãmesẽ-Ðoɖoa ƒe Atikewɔwɔ Ŋuti Nuŋlɔɖigbalẽ 2019; 76: 130-135.https://api.semanticscholar.org/CorpusID: 59338650. Ƒe 1999 ƒe ɣleti gbãtɔ me.

[3] Chamseddin R, Mathew A, Alzohaili O. Abstract #1407986: Abaloparatide dodo to Blewu Patch dzi: Atikewɔwɔ ƒe Tiatia aɖe na Refractory Hypoparathyroidism Post-thyroidectomy. Dɔlékuiwutikewo ƒe Dɔwɔwɔ 2023; 29: S57-S58.DOI: 10.1016/j.eprac.2023.03.131.

[4] Thompson J. C., Wanderman N, Anderson P. A., Ablɔɖe B. A., kple ame bubuwo. Abaloparatide kple Akɔta: Nuŋlɔɖi me Toto. Dɔnɔdzikpɔƒe ƒe Nudede Ame Tsitsi me 2020; 15: 1023-1033 ƒe agbalẽ. DOI:10.2147/CIA.S227611 ƒe agbalẽa.

[5] Landgrave S, Ishii T, Maynard R, kple ame bubuwo. 302 Abaloparatide abe atike yeye aɖe na ƒunukpeƒetetedɔ si dzɔna le afɔku megbe ene. Dɔnɔdzikpɔƒe kple Gbegɔmeɖeɖeŋutinunya ƒe Agbalẽ 2022; 6: 53. DOI: 10.1017/cts.2022.166.

[6] Chandler H, Lanske B, Varela A, kple ame bubuwo. Abaloparatide, si nye osteoanabolic PTHrP analog yeye aɖe, dzia cortical kple trabecular ƒu ƒe lolome kple xɔtuɖaŋu ɖe edzi le orchiectomized rats me to ƒu ƒe wɔwɔme dzi ɖeɖe kpɔtɔ me evɔ medzia ƒu ƒe gbugbɔgaxɔ ɖe edzi o. Ƒu ƒe 2019; 120: 148-155.DOI: 10.1016/j.ƒu.2018.10.012.

[7] Tan B, Wu Y, Wang R, kple ame bubuwo. Biodegradable Nanoflowers kple Abaloparatide Spatiotemporal Dɔwɔna Alveolar Ƒu Gbugbɔgadzɔ. Nano Lɛtawo 2024. https://api.semanticscholar.org/CorpusID:267655299.

[8] Parikh S, Lubitz SE, Sharma A. MON-365 Abaloparatide Zazã Yeye Be Woatsɔ Adzi Aklã ƒe Fusion Dzi Ðe Edzi le Dɔnɔ Si Le Vidzidɔ ƒe Akɔta Gbugbɔgaɖɔɖodɔ Wɔm Me. Dɔlékuiwutikewo ƒe Habɔbɔ ƒe Journal 2020; 4 (Kpekpeɖeŋu_1): 365.DOI: 10.1210 / jendso / bvaa046.108.

NYATAKAKAWO KPLE NUSIWO WOTSƆ ƑE NYATAKAKA SIWO KAtã WOÐO LE NYATAKAKADZRAÐOƑE SIA ME LA KPLE NYATAKAKAWO kaka KPLEE NUFIAFIA ƑE TAÐOÐOWO KO.  

Wotrɔ asi le atike siwo wona le nyatakakadzraɖoƒe sia ŋu na numekuku le vitro ɖeɖeko. Wowɔa numekuku le vitro (Latingbe me: *le ahuhɔ̃e me*, si gɔmee nye le ahuhɔ̃e me) le amegbetɔ ƒe ŋutilã godo. Atike siawo menye atikewo o, United States ƒe Nuɖuɖu Kple Atike Ŋuti Dɔwɔƒe (FDA) meda asi ɖe wo dzi o, eye mele be woazã wo atsɔ axe mɔ ɖe atikewɔwɔ, dɔléle, alo dɔléle aɖeke nu, adae, alo adae o. Se de se vevie be woatsɔ atike siawo ade amegbetɔ alo lãwo ƒe ŋutilã me le mɔ ɖesiaɖe nu.